Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Myotonic Disorders

Tundra lists 4 Myotonic Disorders clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ENROLLING BY INVITATION

NCT07008469

Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1

Gender: All

Ages: 16 Years - Any

Updated: 2026-02-03

16 states

Myotonic Dystrophy Type 1
DM1
Myotonic Dystrophy
+5
ACTIVE NOT RECRUITING

NCT06411288

Global Study of Del-desiran for the Treatment of DM1

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1

Gender: All

Ages: 16 Years - 65 Years

Updated: 2026-01-22

18 states

DM1
Myotonic Dystrophy
Myotonic Dystrophy 1
+7
RECRUITING

NCT07154654

Prospective, Long Term, Observational Study (Patient Registry) of Paediatric Myotonic Disorders

This is a prospective, open-label, multi-centre, single arm, registry study to collect standard relevant clinical and epidemiological data during routine medical evaluation and treatment in paediatric patients with myotonic disorders who are being treated with mexiletine therapy according to the physician.

Gender: All

Ages: Any - 6 Years

Updated: 2025-09-23

Myotonic Disorders
ACTIVE NOT RECRUITING

NCT04622553

Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study.

Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Mexiletine in Paediatric Patients with Myotonic Disorders Who Have Completed the MEX-NM-301 study.

Gender: All

Ages: 6 Years - 18 Years

Updated: 2025-07-25

Myotonic Disorders